

Resource Summary Report

Generated by [PRECISE-TBI](#) on Jul 29, 2026

[pLEX_307](#)

RRID:Addgene_41392

Type: Plasmid

Proper Citation

RRID:Addgene_41392

Plasmid Information

URL: <http://www.addgene.org/41392>

Proper Citation: RRID:Addgene_41392

Bacterial Resistance: Chloramphenicol and Ampicillin

Vector Backbone Description: Backbone Size:10065; Vector Backbone:pLKO; Vector Types:Mammalian Expression, Lentiviral, Gateway Cloning; Bacterial Resistance:Chloramphenicol and Ampicillin

Comments: Plasmid for constitutive lentiviral expression. There is a C-terminal V5 tag followed by a stop codon directly after the Gateway sequence. Alternate plasmid names: pLX307, SV40-puro; EF1a-gateway-V5 tag

Plasmid Name: pLEX_307

Record Creation Time: 20220422T222215+0000

Record Last Update: 20260725T074652+0000

Ratings and Alerts

No rating or validation information has been found for pLEX_307.

No alerts have been found for pLEX_307.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 109 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Tietz KT, et al. (2025) CPSF1 inhibition promotes widespread use of intergenic polyadenylation sites and impairs glycolysis in prostate cancer cells. *Cell reports*, 44(1), 115211.

Diamond B, et al. (2025) Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma. *Blood*, 146(13), 1575.

Liu H, et al. (2025) Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening. *Nature communications*, 16(1), 152.

Baldacci S, et al. (2025) Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapy. *Cancer discovery*.

Moares N, et al. (2025) Dual targeting of BCMA and SLAMF7 with the CARtein system: chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma. *Frontiers in immunology*, 16, 1613222.

Dunlap KN, et al. (2025) SLC7A5 is required for cancer cell growth under arginine-limited conditions. *Cell reports*, 44(1), 115130.

Zhou Z, et al. (2025) Stromal Cell Subsets Show Model-Dependent Changes in Experimental Colitis and Affect Epithelial Tissue Repair and Immune Cell Activation. *Inflammatory bowel diseases*, 31(4), 1051.

Granda Farias A, et al. (2025) Phenotypic screens for SIRPA expression reveal RAB21 as a general regulator of macrophage surface identity. *Cell reports*, 44(7), 115921.

Gonzalez-Garcia P, et al. (2025) Intein-based modular chimeric antigen receptor platform for specific CD19/CD20 co-targeting. *Molecular oncology*.

Resnick SJ, et al. (2025) Multiplex neurodegeneration proteotoxicity platform reveals DNAJB6 promotes non-toxic FUS condensate gelation and inhibits neurotoxicity. *Nature communications*, 16(1), 10285.

Roth JS, et al. (2025) PRMT5 activity sustains histone production to maintain genome integrity. *bioRxiv : the preprint server for biology*.

Bourne CM, et al. (2025) A Potent Inhibitor of Caspase-8 Based on the IL-18 Tetrapeptide Sequence Reveals Shared Specificities between Inflammatory and Apoptotic Initiator Caspases. *ACS bio & med chem Au*, 5(4), 565.

Yee PS, et al. (2025) Interferon-Inducible ADAR1 p150 Is Essential for the Survival of Oral Squamous Cell Carcinoma. *Molecular carcinogenesis*, 64(6), 1066.

Duan S, et al. (2025) WNK1 signalling regulates amino acid transport and mTORC1 activity to sustain acute myeloid leukaemia growth. *Nature communications*, 16(1), 4920.

Selcen S, et al. (2025) Integrated real-time imaging of executioner caspase dynamics, apoptosis-induced proliferation, and immunogenic cell death using a stable fluorescent reporter platform. *Cell death discovery*, 11(1), 368.

Tamura T, et al. (2025) mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer. *Cancer letters*, 616, 217565.

Gui L, et al. (2025) Targeting the mevalonate pathway potentiates NUAK1 inhibition-induced immunogenic cell death and antitumor immunity. *Cell reports. Medicine*, 6(2), 101913.

Giddins M, et al. (2025) Combinatorial protein engineering identifies potent CRISPR activators with reduced toxicity. *Nature communications*, 16(1), 11114.

Saavedra-Sanchez L, et al. (2025) The *Shigella flexneri* effector IpaH1.4 facilitates RNF213 degradation and protects cytosolic bacteria against interferon-induced ubiquitylation. *eLife*, 13.

Mahieu CI, et al. (2024) ORAOV1, CCND1, and MIR548K Are the Driver Oncogenes of the 11q13 Amplicon in Squamous Cell Carcinoma. *Molecular cancer research : MCR*, 22(2), 152.